Asset Details
Do you wish to reserve the book?
A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
Do you wish to request the book?
A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
2020
Overview
In a randomized trial involving schizophrenic patients with acute psychosis, a new oral drug that does not have a dopamine D2-receptor–binding mechanism of action led to a greater reduction in the severity of overall symptoms than placebo over 4 weeks. The incidence of extrapyramidal symptoms was 3% with the new drug, a finding similar to that with placebo.
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Antipsychotic Agents - adverse effects
/ Antipsychotic Agents - therapeutic use
/ Dopamine
/ Drug Administration Schedule
/ Female
/ Humans
/ Lipids
/ Male
/ Neurons
/ Patients
/ Receptors, G-Protein-Coupled - agonists
/ Schizophrenia - classification
/ Schizophrenia - drug therapy
